Skip to main content

Table 2 A univariate Cox regression and a variable selection logistic regression for confounding factors based on Transfusion and No-transfusion

From: Perioperative blood transfusion does not affect recurrence-free and overall survivals after curative resection for intrahepatic cholangiocarcinoma: a propensity score matching analysis

Characteristic Variables Before PSM
Univariate (OS, COX Regression) Univariate (DFS, COX Regression) Univariate (Logistic Regression) Multivariate (Logistic Regression)
HR (95% CI) P valuea HR (95% CI) P valuea OR (95% CI) P valuea OR (95% CI) P valuea
Age Y ± SD 1.007 (0.998–1.017) 0.131 1.006 (0.997–1.014) 0.219 0.993 (0.973–1.013) 0.477   
Gender female reference 0.121 reference 0.145 reference 0.009 reference 0.506
male 1.184 (0.956–1.466)   1.163 (0.949–1.425)   0.553 (0.355–0.863)   0.790 (0.393–1.585)  
Preoperative Hb g/L ± SD 0.988 (0.981–0.994) <0.001 0.990 (0.985–0.996) 0.001 0.951 (0.937–0.965) <0.001 0.947 (0.927–0.967) <0.001
Platelet 1 × 109/L ± SD 1.001 (1.000–1.003) 0.177 1.001 (0.999–1.002) 0.222 1.004 (1.001–1.007) 0.006 1.001 (0.997–1.006) 0.537
Total bilirubin umol/L + SD 1.003 (1.002–1.004) <0.001 1.002(1.001–1.003) 0.001 1.007 (1.005–1.010) <0.001 1.006 (1.003–1.009) <0.001
AST U/L ± SD 1.000 (0.999–1.002) 0.487 1.001 (1.000–1.002) 0.205 1.001 (0.999–1.003) 0.24   
ALT U/L ± SD 1.001 (1.000–1.002) 0.029 1.001 (1.000–1.002) 0.049 1.001 (0.999–1.003) 0.472   
AFP ng/mL ± SD 1.000 (1.000–1.000) 0.379 1.000 (1.000–1.000) 0.451 1.000 (1.000–1.000) 0.983   
CEA ng/mL ± SD 1.000 (1.000–1.000) 0.745 1.001 (1.000–1.001) 0.01 1.001 (1.000–1.002) 0.108   
CA19–9 U/mL ± SD 1.000 (1.000–1.000) <0.001 1.000 (1.000–1.000) <0.001 1.000 (1.000–1.000) <0.001 1.000 (1.000–1.000) 0.903
PT s ± SD 1.000 (0.988–1.012) 0.99 1.008 (0.994–1.022) 0.28 1.007 (0.986–1.028) 0.507   
INR Value ±SD 2.307 (0.949–5.605) 0.065 1.692 (0.742–3.855) 0.211 0.714 (0.095–5.388) 0.744   
HBsAg (−) reference 0.401 reference 0.232 reference 0.003 reference 0.126
(+) 0.912 (0.737–1.130)   0.882 (0.718–1.084)   0.459 (0.275–0.764)   0.552 (0.258–1.183)  
Anti-HCV (−) reference 0.04 reference 0.076 reference 0.814   
(+) 0.395 (0.163–0.956)   0.507 (0.240–1.073)   1.204 (0.256–5.663)   
Tumor number 1 reference 0.446 reference 0.559 reference 0.261   
>1 1.122 (0.835–1.507)   1.088 (0.821–1.441)   0.681 (0.348–1.332)   
TMD cm 1.052 (1.017–1.087) 0.003 1.057 (1.025–1.090) <0.001 1.041 (0.975–1.113) 0.229   
TNM stage I reference <0.001 reference 0.001 reference 0.784   
II 1.105 (0.804–1.518)   1.192 (0.882–1.611)   1.173 (0.624–2.206)    
III 2.167 (1.104–4.255)   1.823 (0.961–3.455)   0.000(0.000-.)    
IVa 2.088 (1.592–2.739)   1.657 (1.273–2.157)   0.766 (0.390–1.503)    
Cirrhotic nodule no reference 0.274 reference 0.799 reference 0.067   
yes 1.127 (0.910–1.397)   1.028 (0.834–1.266)   0.614 (0.365–1.035)    
DD I reference 0.982 reference 0.997 reference 1.000   
II-III 2997.401 (0.000-.)   8142.694 (0.000-.)   300,921,742.177 (0.000-.)  
IV 2632.881 (0.000-.)   8450.077 (0.000-.)   1.000 (0.000-.)    
IBL <1000 mL reference 0.005 reference 0.002 reference <0.001 reference <0.001
≥1000 mL 1.733 (1.184–2.535)   1.816 (1.243–2.652)   65.443 (22.383–191.341) 168.205 (43.249–654.184)  
Preventive TACE no reference 0.349 reference 0.144 reference 0.972   
yes 0.841 (0.585–1.209)   1.300 (0.914–1.848)   1.015 (0.439–2.348)   
  1. OS: overall survival; DFS: disease-free survival; OR: odd ratio; HR: hazard ratio; “.”: indicate the exceeded value
  2. alikelihood ratio test